ArticleResearch and practice in thrombosis and haemostasis2026
Menstrual outcomes are frequently overlooked in von Willebrand disease trials.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite autosomal inheritance, females are disproportionately impacted by von Willebrand disease (VWD) due to heavy menstrual bleeding (HMB). HMB remains the most frequently reported and severe bleeding symptom in females with VWD. Nevertheless, interventional studies of VWD prophylaxis frequently fail to include or report menstrual-related outcomes. Objectives: This study evaluated the inclusion of menstrual and female-specific outcomes in clinical interventional trials of VWD prophylaxis. Methods: US (Clinicaltrials.gov), Canadian (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/health-canada-clinical-trials-database.html), and European (clinicaltrialsregister.eu) databases were searched for VWD interventional studies open to females with VWD aged >12 years between 2014 and 2024. Two reviewers assessed all studies, excluding those not focused on prophylaxis or duplicates. Inclusion criteria, outcomes, and publications were reviewed for menstrual-related data. Results: Initially, 42 interventional studies were identified; following exclusions, 10 studies remained. Only 2 of 10 (20%) studies incorporated menstrual inclusion criteria. Furthermore, 4 of 10 studies specifically excluded treated menstrual bleeding in their bleed eligibility criteria. Annualized bleeding rates were collected in 8 of 10 (80%) studies but menstrual outcomes in only 4 of 10 (40%). Most studies with results posted ( Conclusion: Clinical trials in VWD frequently use outcomes adapted from hemophilia studies (eg, annualized bleeding rates) rather than tailoring to the needs of females with VWD. Until we address this issue, we will lack clarity on optimal treatment, including the role of prophylaxis for the management of HMB in females with VWD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.